Destiny Pharma (LON:DEST) released its quarterly earnings data on Thursday. The company reported GBX (8.40) (($0.12)) earnings per share (EPS) for the quarter, missing the consensus estimate of GBX (8.30) (($0.12)) by GBX (0.10) ($0.00), Bloomberg Earnings reports.
LON DEST opened at GBX 129 ($1.82) on Friday. Destiny Pharma has a 1-year low of GBX 111 ($1.57) and a 1-year high of GBX 235 ($3.32).
Separately, FinnCap reissued a “corporate” rating and set a GBX 250 ($3.53) price target on shares of Destiny Pharma in a report on Thursday.
Destiny Pharma Company Profile
Destiny Pharma plc, a biotechnology company, focuses on the development of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.